Technical Analysis for PXMD - PaxMedica, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Jack-in-the-Box Bullish | Bullish Swing Setup | -12.34% | |
| Upper Bollinger Band Walk | Strength | -12.34% | |
| Inside Day | Range Contraction | -12.34% | |
| Wide Bands | Range Expansion | -12.34% | |
| Upper Bollinger Band Touch | Strength | -12.34% | |
| Expansion Breakout | Bullish Swing Setup | -21.97% | |
| Pocket Pivot | Bullish Swing Setup | -21.97% | |
| Wide Range Bar | Range Expansion | -21.97% | |
| Stochastic Reached Overbought | Strength | -21.97% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 1 ATR | about 7 hours ago |
| 60 Minute Opening Range Breakdown | about 11 hours ago |
| Fell Below 10 DMA | about 12 hours ago |
| 10 DMA Support | about 13 hours ago |
| Down 5% | about 13 hours ago |
Get this analysis on your stocks daily!
- Earnings date: ???
PaxMedica, Inc. Description
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Disorders Chronic Condition Drug Therapies Autism Spectrum Disorder Chronic Fatigue Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.48 |
| 52 Week Low | 1.36 |
| Average Volume | 1,131,801 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 2.23 |
| 20-Day Moving Average | 2.51 |
| 10-Day Moving Average | 2.84 |
| Average True Range | 0.45 |
| RSI | 53.49 |
| ADX | 38.08 |
| +DI | 30.54 |
| -DI | 13.81 |
| Chandelier Exit (Long, 3 ATRs) | 2.39 |
| Chandelier Exit (Short, 3 ATRs) | 2.72 |
| Upper Bollinger Bands | 3.32 |
| Lower Bollinger Band | 1.69 |
| Percent B (%b) | 0.62 |
| BandWidth | 64.80 |
| MACD Line | 0.25 |
| MACD Signal Line | 0.20 |
| MACD Histogram | 0.0518 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.60 | ||||
| Resistance 3 (R3) | 3.65 | 3.40 | 3.45 | ||
| Resistance 2 (R2) | 3.40 | 3.17 | 3.37 | 3.40 | |
| Resistance 1 (R1) | 3.05 | 3.03 | 2.92 | 3.00 | 3.35 |
| Pivot Point | 2.80 | 2.80 | 2.74 | 2.77 | 2.80 |
| Support 1 (S1) | 2.45 | 2.57 | 2.33 | 2.40 | 2.05 |
| Support 2 (S2) | 2.20 | 2.43 | 2.18 | 2.00 | |
| Support 3 (S3) | 1.85 | 2.20 | 1.95 | ||
| Support 4 (S4) | 1.80 |
